Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15837592 | 0.77 | PIK3CD (0.38) | DPP4DPP7EPHX2EPHX1CPN1 | |
| SCHEMBL679537 | 0.77 | PIK3CD (0.38) | DPP4DPP7EPHX2EPHX1CPN1 | |
| SCHEMBL15837591 | 0.77 | PIK3CD (0.38) | DPP4DPP7EPHX2EPHX1CPN1 | |
| SCHEMBL19030414 | 0.76 | CPN1 (0.34) | DPP4DPP7CPN1CPB2 | |
| SCHEMBL17572000 | 0.75 | EPHX2 (0.43) | DPP4DPP7EPHX2EPHX1CPN1 | |
| SCHEMBL17518799 | 0.73 | NCF1 (0.31) | — | |
| SCHEMBL24449425 | 0.70 | DPP4 (0.39) | DPP4DPP7EPHX2EPHX1CPN1 | |
| SCHEMBL18711730 | 0.70 | SPR (0.38) | DPP4DPP7EPHX2EPHX1CPN1 | |
| SCHEMBL19030609 | 0.70 | HPGD (0.50) | DPP4EPHX1 | |
| SCHEMBL6277604 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809545-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160046581-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046581-A1 | Factor XIa Inhibitors | F11, F12, TFPI | DPP4 2474/4885DPP7 2732/4885PDE4B 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.